Skip to content
DataLookout
Menu

NCT06996951

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jul 2026 to Jul 2027
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description revised
  2. Notable Primary endpoints: 4 to 7v4 Show 4 more changesShow less
    • Start date: Jun 16, 2025 to Jul 2, 2025
    • Interventions: :PULMONARY FUNCTION TEST (Diagnostic Test), CYSTIC FIBROSIS QUESTIONNAIRE-REVISED (Behavioral), LEUKOSORB FILTER PAPER APPLICATION TO NASAL… to CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID (Drug), STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID (Other)
    • Secondary endpoint revised
    • Study description shortened, about 1 word
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  4. Notable Phase: Not applicable to Phase 3
    • Study sites: 0 to 1
    • Start date: May 2025 to Jun 16, 2025
    v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Lund Kennedy Score
Timeframe: Baseline, 12 weeks
Change in Pulmonary Function Testing
Timeframe: Baseline, 12 weeks
Change in Body Mass Index (BMI)
Timeframe: Baseline, 12 weeks
Change in Health Care Utilization
Timeframe: Baseline, 12 weeks
Change in Sinonasal Outcome Test 22 Questionnaire (SNOT-22) Score
Timeframe: Baseline, 12 weeks
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score
Timeframe: Baseline, 12 weeks
Change in Patient Health Questionnaire-9 (PHQ-9) Score
Timeframe: Baseline, 12 weeks

Secondary (1)

Change in nasal mucous biomarkers.

Arms and interventions

CONTINUE TOPICAL STEROID NASAL IRRIGATIONActive comparator

PARTICIPANTS WILL CONTINUE THEIR NASAL TREATMENT WHICH WAS ALREADY PRESCRIBED BY THEIR PHYSICIAN

STOP TOPICAL NASAL TREATMENTExperimental

PARTICIPANTS IN THIS ARM WILL BE ASKED TO STOP THEIR NASAL TREATMENT

Other: STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

Drugs: CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

Sites

1 site in 1 country

  • Indiana University HealthIndianapolis, Indiana, United States